Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIOPEN HR-NBL2 high-risk neuroblastoma phase 3 platform study
2024-514917-36-00Phase 3Authorised
- Sponsor
- Gustave Roussy
- Start
- Nov 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, open-label trial of Dinutuximab beta, temozolomide, irinotecan, busulfan, melphalan and 6 more in neuroblastoma (6 arms), sponsored by Gustave Roussy. Primary endpoints: 3-year event-free survival for R-HDC, 3-year event-free survival for R-RTx and 1 more. Planned start Nov 2024; status: authorised.
02
Drugs
Dinutuximab betatemozolomideirinotecanbusulfanmelphalan
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on 2024-514917-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514917-36-00.